China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis

Zai Lab Ltd

NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.
Phase 3 ADAPT: 68% responders on MG-ADL vs 30% placebo (p<0.0001) in first cycle.
Zai Lab to seek National Reimbursement Drug List inclusion for broader patient access.
Zai Lab holds exclusive license from argenx to develop/commercialize in mainland China, HK, Macau, Taiwan.
VYVGART is the first approved FcRn antagonist for gMG in China; ~200,000 MG patients in country.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.